Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.78 |
| ▸ | NPC1 | O15118 | 3/20 | 0.78 |
| ▸ | RAB9A | P51151 | 3/20 | 0.78 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.77 |
| ▸ | ANO1 | Q5XXA6 | 12/20 | 0.74 |
| ▸ | PRNP | P04156 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628135 | 1.00 | MEN1 (0.78) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL3631114 | 0.94 | ANO1 (0.83) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL21259152 | 0.89 | MEN1 (0.80) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL3630966 | 0.89 | MEN1 (0.77) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL12271278 | 0.89 | ANO1 (0.80) | MEN1KMT2ARAB9AGRIN2CANO1 | |
| SCHEMBL28583539 | 0.88 | GRIN2C (0.81) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL3622116 | 0.88 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL3629710 | 0.88 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL12314174 | 0.88 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AGRIN2C | |
| SCHEMBL3630211 | 0.88 | MEN1 (0.78) | MEN1KMT2ANPC1RAB9AANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263641-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2012-09-11 | — | — | US | claimed |
| EP-2200607-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| US-20090137659-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2009035818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2009-03-19 | — | — | WO | claimed |
| US-8524765-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120289587-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-8263641-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2200607-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20090137659-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009035818-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289587-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MEN1 2958/4885KMT2A 4706/4885NPC1 262/4885 |
| US-20090137659-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MEN1 2958/4885KMT2A 4706/4885NPC1 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.